Condition

Open Angle Glaucoma or Ocular Hypertension

ClinicalTrials.gov condition label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 4 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials4

Recruiting0

Common interventions7

Lead sponsors shown2

Clinical trials

4 shown

OPC-1085EL in the Treatment of Primary Open Angle Glaucoma or Ocular Hypertension in Chinese SubjectsNCT05583474 · 2022-09-27

COMPLETED

A Phase III Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution Compared With Latanoprost Ophthalmic Solution in Subjects With OAG or OHTNCT02981446 · 2017-01-01

COMPLETED

A Long-term Study of DE-117 Ophthalmic Solution Monotherapy and Concomitant Use of DE-117 Ophthalmic Solution With Timolol Ophthalmic Solution in Patients With OAG or OH: RENGE StudyNCT02822729 · 2016-07-01

COMPLETED

DE-111 Ophthalmic Solution in Patients With Open Angle Glaucoma or Ocular HypertensionNCT01343082 · 2011-05-01

COMPLETED

Common interventions

0.005% LatanoprostDRUG1 DE-111 ophthalmic solutionDRUG1 DE-117DRUG1 DE-117 ophthalmic solutionDRUG1 Latanoprost ophthalmic solutionDRUG1 OPC-1085ELDRUG1 Timolol ophthalmic solutionDRUG1

Leading sponsors

Santen Pharmaceutical Co., Ltd. 3 Otsuka Beijing Research Institute 1

Trial status mix

COMPLETED4

Phase mix

PHASE34

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.